Recombinant Human IL-12 R beta 1 / CD212 Protein, His Tag, 100 µg

Background
The human IL-12 R subunit is a member of the cytokine receptor superfamily and the functional high-affinity IL-12R is composed of at least two beta-type cytokine receptor subunits, each independently exhibiting a low affinity for IL-12. IL-12 R beta 1 (Interleukin-12 receptor subunit beta-1) is also known as IL-12RB1, CD212. Functions as an interleukin receptor which binds interleukin-12 with low affinity and is involved in IL12 transduction. Associated with IL12RB2 it forms a functional, high affinity receptor for IL12. Associates also with IL23R to form the interleukin-23 receptor which functions in IL23 signal transduction probably through activation of the Jak-Stat signaling cascade.

Source
Recombinant Human IL-12 R beta 1, His Tag (ILB-H52H9) is expressed from human 293 cells (HEK293). It contains AA Cys 24 - Glu 540 (Accession # P42701-1).
Predicted N-terminus: Cys 24

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 59.0 kDa. The protein migrates as 64-68 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Memory-like differentiation enhances NK cell responses against colorectal cancer"
Marin, Becker-Hapak, Song et al
Oncoimmunology (2024) 13 (1), 2348254
(2) "Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial"
Yarchoan, Gane, Marron et al
Nat Med (2024) 30 (4), 1044-1053
(3) "The causal association between circulating cytokines with the risk of frailty and sarcopenia under the perspective of geroscience"
Wang, Wang, Wan et al
Front Endocrinol (Lausanne) (2024) 15, 1293146
Showing 1-3 of 148 papers.